Aktien Sensor

Eli Lilly’s stock price has plummeted 15% after investors lost faith in the company’s weight-loss pill, which is struggling to compete with Novo Nordisk’s market-leading semaglutide.

Sandoz Group AG reports strong financial results for the first half of 2025, driven by 12% growth in biosimilars sales and a 20.0% core EBITDA margin.

Novartis’ stock price sees a modest increase amid rumors of potential takeover talks with US biotech firm Avidity Biosciences.

Cigna Group’s stock price surges after Deutsche Bank raises price target, but investors are left waiting for concrete financial details.

Natera Inc’s stock price has surged 32% year-over-year after the biotechnology company reported strong second-quarter earnings, exceeding revenue expectations and prompting analysts to raise their price targets.

Smith & Nephew PLC has reported a strong first-half performance, driven by revenue growth, margin expansion, and a strategic share buyback plan, leading to analyst upgrades and a positive outlook for the company.

The company’s annual meeting and board meeting have led to significant developments, including a new vaccine production and a major aircraft order.

Teva Pharmaceutical Industries Ltd. has navigated a volatile market, but a recent FDA approval of its migraine treatment Ajovy for children and adolescents is expected to boost the company’s stock price and drive long-term growth.

Royalty Pharma PLC reported mixed Q2 earnings, with revenue surging but profit declining, but raised its 2025 financial guidance despite the setback.

Eisai Co Ltd reports a 15.62% increase in quarterly revenue, driven by expansion of its product portfolio and increased market presence.